Select your country or region to view content specific to your country.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in each country.
Nov 15, 2021
Seegene, which participated in the 34th International Papillomavirus Conference (hereinafter "IPVC") as a gold sponsor, held an online symposium from November 15 to 19, stressing the need for using genotyping products for primary tests for human papillomavirus (hereinafter "HPV").
In a
90-minute online session on “HPV Genotyping Distribution in Target Population”, Dr. Daniel Guerendiain from Scotland presented on “Anal Cancer and AIN Data Tested with Seegene's Anyplex™II HPV28 Assay” and Dr. David Hawkes from
Australia presented on the “HPV-based Cervical
Screening in a National Program with Age-based Vaccinated and Non-vaccinated
Cohorts”. In particular, Dr. Hugo Sousa from Portugal
proposed that different clinical approaches should be taken for each HPV
genotype based on the distribution of high-risk HPV infection among clinically
tested cervical cancer screenings in northern Portugal.
Although the
entire session was hosted online this year due to the coronavirus, the Seegene
symposium was successfully conducted with 148 people participating from 46
countries and more than 150 people visiting the Seegene booth during the
conference. IPVC is hosted in a different continent every 16 months, and 1,259
people from a total of 89 countries participated online this year.